Abstract
Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.
Trial registration:
ClinicalTrials.gov NCT00585195.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Anaplastic Lymphoma Kinase
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Carboplatin / administration & dosage
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Crizotinib
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Epithelial-Mesenchymal Transition / drug effects*
-
Female
-
Gemcitabine
-
Gene Amplification*
-
Humans
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins c-met / genetics*
-
Pyrazoles / therapeutic use*
-
Pyridines / therapeutic use*
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Receptors, Growth Factor / genetics*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyridines
-
Receptors, Growth Factor
-
Deoxycytidine
-
Bevacizumab
-
Crizotinib
-
Carboplatin
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
MET protein, human
-
Proto-Oncogene Proteins c-met
-
Receptor Protein-Tyrosine Kinases
-
Gemcitabine
Associated data
-
ClinicalTrials.gov/NCT00585195